A Phase 2 interventional study of Rivaroxaban (Xarelto, BAY59-7939) in Venous Thrombosis and Deep Vein Thrombosis, sponsored by Bayer. Completed at 16 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-11-18.
Sponsored by Bayer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing rivaroxaban in Venous Thrombosis — 5 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Venous Thrombosis.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, this one is the 35th largest by enrollment, is the only one that started in 2009, is one of 4 in phase 2, and was the 3rd registered.
785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.
Browse Venous Thrombosis studies →5 of the 36 studies testing rivaroxaban in Venous Thrombosis are open now, in 6 countries. Recruiting first, the newest first:
Mayo Hospital Lahore · Sites in Pakistan
Ages 18–80
Prof. Stavros Konstantinides, MD · Sites in Austria, Germany
Ages 18–85
University Hospital, Angers · Sites in France
Ages 18+
Science Valley Research Institute · Sites in Brazil
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 10
First in 2004; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 152 across 477 interventional studies indexed under Venous Thrombosis.
Median enrollment 120 across the 36 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
23 studies in Venous Thrombosis by Bayer: none open now, none under way, none of them phase 3. Of 23 finished, 6 (26%) have results posted.
Among the 23 studies in Venous Thrombosis by Bayer, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2009, is one of 5 in phase 2, and was the 3rd registered.
Bayer’s Venous Thrombosis studies by the year they started, since 2004.
3 of the studies testing rivaroxaban in Venous Thrombosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06611319Phase 3Prof. Stavros Konstantinides, MDENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty | 2027-03 |
| NCT04694248First Affiliated Hospital of Zhejiang UniversityAnticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting | 2026-12-31 |
| NCT03129555Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing rivaroxaban in Venous Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 23 in Venous Thrombosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450 isoenzyme 3A4 (CYP 3A4) inducer for the entire 3-month study duration.
The following laboratory variables were determined at baseline at the local laboratories: Hemoglobin, platelets, activated partial thromboplastin time (aPTT), international normalized ratio (INR), alanine aminotransferase (ALT), and creatinine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
Pharmacodynamics - Prothrombin Time (PT), Baseline Value
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Mean and standard deviation (SD) values are presented for PT baseline.
Time frame: The baseline value of prothrombin time is measured or calculated at a rivaroxaban concentration of 0 µg/L and is based on the observations that were made during the 3 months treatment period
Pharmacodynamics - Prothrombin Time (PT), Slope
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out of PT is in seconds. The PT slope describes the linear increase of PT for one unit increase in concentration, thus the unit of PT slope is s\*(µg/L)\^-1. The final population PK/PD model included a fixed slope that was fitted to the data of the 19 patients that were eligible for evaluation. The estimated mean value (fixed/ the same for all patients in this study) is presented for PT slope.
Time frame: Up to 3 months treatment
Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban
AUC(0-24)ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inducer.
Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban
Pharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban
Cmax,ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.
Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban
Pharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban
Cmin,ss was predicted for each individual participant from rivaroxaban plasma concentrations and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.
Time frame: 0 (predose), 1, 2, 3, 4, 6, 8, 12, and 24 h after first administration of rivaroxaban
Percentage of Participants With Clinically Relevant Bleeding (i.e. Major Bleeding and Clinically Relevant Non-major Bleeding)
All events were adjudicated and confirmed by a central independent adjudication committee. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
Time frame: Up to 3 months treatment and during subsequent 2 days
Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Non-fatal or Fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment
All events were adjudicated and confirmed by a central independent adjudication committee. The composite efficacy outcome symptomatic recurrent VTE was analyzed descriptively, with the components: Death due to PE, death for which PE cannot be excluded, symptomatic PE and DVT, symptomatic recurrent PE only, and symptomatic recurrent DVT only up to the end of intended treatment period (3 months; 98 study days) and on-treatment (up to 2 days after stop of study drug).
Time frame: Up to 3 months treatment and during subsequent 30-day observational period for an individual participant
Percentage of Participants With All Deaths
All deaths were adjudicated by a central independent adjudication committee. Participants who died for any reason were counted for this measure.
Time frame: Up to 3 months and on-treatment (up to 2 days after stop of study drug) plus an observational period planned for one month
Percentage of Participants With Treatment Emergent Deaths - 7 Days Window
Treatment emergent deaths were adjudicated by a central independent adjudication committee. Participants who died from treatment emergent adverse events were counted for this measure.
Time frame: Up to 3 months treatment and during subsequent 7 days
Percentage of Participants With Other Vascular Events
All events were adjudicated and confirmed by a central independent adjudication committee. Other vascular events comprised ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), unstable angina (UA), ischemic stroke, transient ischemic attack (TIA), non-central nervous system systemic embolism and vascular death.
Time frame: Up to 3 months treatment and during subsequent 1 day
Participants with confirmed acute proximal symptomatic deep vein thrombosis (DVT) or acute pulmonary embolism (PE) were recruited at specialized study sites.
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Started | 25 |
| Completed | 14 |
| Not completed | 11 |
| Withdrew: Death | 2 |
| Withdrew: Final visit earlier than planned | 3 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Non-compliance with study drug treatment | 1 |
| Withdrew: Adverse event | 2 |
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Started | 20 |
| Completed | 17 |
| Not completed | 3 |
| Withdrew: Death | 1 |
| Withdrew: End-of-study done up to 4 days early | 2 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out is in seconds. Mean and standard deviation (SD) values are presented for PT baseline.
| Seconds | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Pharmacodynamics - Prothrombin Time (PT), Baseline Value | 15.8 ± 1.49 |
Prothrombin time (PT) is a global clotting test assessing the extrinsic pathway of the blood coagulation cascade. The test is sensitive for deficiencies of Factors II, V, VII, and X, with sensitivity being best for Factors V, VII, and X and less pronounced for Factor II. The initial read-out of PT is in seconds. The PT slope describes the linear increase of PT for one unit increase in concentration, thus the unit of PT slope is s\*(µg/L)\^-1. The final population PK/PD model included a fixed slope that was fitted to the data of the 19 patients that were eligible for evaluation. The estimated mean value (fixed/ the same for all patients in this study) is presented for PT slope.
| s*(µg/L)^-1 | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Pharmacodynamics - Prothrombin Time (PT), Slope | 0.0389 ± NA |
AUC(0-24)ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong cytochrome P450 isoenzyme 3A4 (CYP3A4) inducer.
| (µg*h)/L | Rivaroxaban Initial Treatment | Rivaroxaban Extended Treatment |
|---|---|---|
| Pharmacokinetics - AUC(0-24)ss (Area Under the Measurement Versus Time Curve From Time 0 to 24 Hours After First Dosing on a Day at Steady State) of Rivaroxaban | 2836 (1259 to 6877) | 2319 (1059 to 5782) |
Cmax,ss was predicted from rivaroxaban plasma concentrations for each individual participant and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.
| µg/L | Rivaroxaban Initial Treatment | Rivaroxaban Extended Treatment |
|---|---|---|
| Pharmacokinetics - Cmax,ss (Maximum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban | 200 (150 to 386) | 167 (126 to 324) |
Cmin,ss was predicted for each individual participant from rivaroxaban plasma concentrations and was only considered for the time period during which participants concomitantly received rivaroxaban and a strong CYP3A4 inducer.
| µg/L | Rivaroxaban Initial Treatment | Rivaroxaban Extended Treatment |
|---|---|---|
| Pharmacokinetics - Cmin,ss (Minimum Observed Drug Concentration in Measured Matrix at Steady State During a Dosage Interval) of Rivaroxaban | 42 (1 to 170) | 35 (1 to 143) |
All events were adjudicated and confirmed by a central independent adjudication committee. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Any confirmed bleeding | 12.0 |
| Clinically relevant non-major bleeding | 8.0 |
| Trivial bleeding | 8.0 |
All events were adjudicated and confirmed by a central independent adjudication committee. The composite efficacy outcome symptomatic recurrent VTE was analyzed descriptively, with the components: Death due to PE, death for which PE cannot be excluded, symptomatic PE and DVT, symptomatic recurrent PE only, and symptomatic recurrent DVT only up to the end of intended treatment period (3 months; 98 study days) and on-treatment (up to 2 days after stop of study drug).
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| symptomatic recurrent VTE (composite) | 8.0 |
| Death | 4.0 |
| Symptomatic recurrent deep vein thrombosis only | 4.0 |
All deaths were adjudicated by a central independent adjudication committee. Participants who died for any reason were counted for this measure.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Percentage of Participants With All Deaths | 12.0 |
Treatment emergent deaths were adjudicated by a central independent adjudication committee. Participants who died from treatment emergent adverse events were counted for this measure.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Percentage of Participants With Treatment Emergent Deaths - 7 Days Window | 8.0 |
All events were adjudicated and confirmed by a central independent adjudication committee. Other vascular events comprised ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), unstable angina (UA), ischemic stroke, transient ischemic attack (TIA), non-central nervous system systemic embolism and vascular death.
| Percentage of participants | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Percentage of Participants With Other Vascular Events | 0.0 |
Collected over For the whole study, adverse event (AE) data were collected during the study course of 25 months. For the individual patient, AE were collected during a treatment period planned for three months plus an observational period planned for one month.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | — | 5/25 (20%) | 14/25 (56%) |
| Event | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| DeathGeneral disorders | 2/25 |
| Sudden deathGeneral disorders | 1/25 |
| HepatitisHepatobiliary disorders | 1/25 |
| Meningitis cryptococcalInfections and infestations | 1/25 |
| Vascular dementiaNervous system disorders | 1/25 |
| Event | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Urinary tract infectionInfections and infestations | 3/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/25 |
| NeutropeniaBlood and lymphatic system disorders | 1/25 |
| TachycardiaCardiac disorders | 1/25 |
| HaemorrhoidsGastrointestinal disorders | 1/25 |
| OedemaGeneral disorders | 1/25 |
| Oedema peripheralGeneral disorders | 1/25 |
| CellulitisInfections and infestations | 1/25 |
| HIV test positiveInvestigations | 1/25 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/25 |
| Age, Customized(Participants) | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| < 65 years | 23 |
| 65 - 75 years | 1 |
| > 75 years | 1 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| Female | 13 |
| Male | 12 |
| Race(Participants) | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| White | 1 |
| Black | 23 |
| Other (mixed South African descent) | 1 |
| Creatinine clearance(Participants) | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| <30 mL/min | 0 |
| 30 - <50 mL/min | 0 |
| 50 - <80 mL/min | 4 |
| > 80 mL/min | 21 |
| Region of recruitment(Participants) | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| South Africa - Yes | 25 |
| South Africa - No | 0 |
| Participants with history of tuberculosis(Participants) | Rivaroxaban (Xarelto, BAY59-7939) |
|---|---|
| History of tuberculosis | 20 |
| No history of tuberculosis | 5 |
The record gives a start of May 2009, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 3 years 1 month after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban